FAQ Library

FAQ Library published on February 10, 2016
Join Dr. Hetty Carraway in this Managing MDS FAQ where she discusses the most serious treatment-related adverse effects in elderly patients with MDS.
FAQ Library published on January 13, 2016
Join Dr. Garcia-Manero in this Managing MDS FAQ as he explains which treatments should be used in lower-risk MDS patients who have failed therapy with erythropoietic stimulating agents.
FAQ Library published on December 18, 2015
Join Dr. Garcia-Manero in this Managing MDS FAQ as he not only explains the difference between the IPSS and the IPSS-R but also why you should use the IPSS-R in your patients.
FAQ Library published on May 20, 2015
Dr. Moreno Festuccia describes the best prognostic classification of patients with CMML, which was originally included in the French-American-British classification of myelodysplastic syndromes.
FAQ Library published on May 20, 2015
Dr. Moreno Festuccia explains the importance of sending an MDS patient for a second opinion prior to starting any active drug.
FAQ Library published on May 7, 2015
Dr. Raza discusses two situations, patients with and without deletion 5q, where the use of lenalidomide is desirable.
FAQ Library published on May 7, 2015
Dr. Raza discusses the treatment options and knowledge gaps in the therapeutic landscape of MDS.
FAQ Library published on March 6, 2015
Dr. Bart Scott discusses whether you would consider lenalidomide for patients with MDS who do not have deletion 5q.
FAQ Library published on March 6, 2015
Dr. Bart Scott discusses the recent treatments for MDS, how they compare, and the appropriate times to use each individual therapy.
FAQ Library published on March 6, 2015
Dr. Bart Scott discusses the role patient education and communication play in the overall outcome of treatment.
Page 4 of 6
Results 31 - 40 of 57

Managing MDS would like to recognize and thank Celgene Corporation for their educational support of ManagingMDS.com

©2017 MediCom Worldwide, Inc. All rights reserved